Search details
1.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood
; 140(10): 1104-1118, 2022 09 08.
Article
in English
| MEDLINE | ID: mdl-35878001
2.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Ann Hematol
; 103(1): 259-268, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37861736
3.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2499-2512, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37041225
4.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Blood
; 138(24): 2499-2513, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34166502
5.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Article
in English
| MEDLINE | ID: mdl-34724563
6.
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Cytotherapy
; 25(9): 986-992, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37055322
7.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Eur J Nucl Med Mol Imaging
; 50(5): 1406-1413, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36513818
8.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37584447
9.
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Haematologica
; 107(9): 2096-2107, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35172565
10.
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.
BMC Infect Dis
; 21(1): 121, 2021 Jan 28.
Article
in English
| MEDLINE | ID: mdl-33509115
11.
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Blood
; 140(20): 2175-2179, 2022 11 17.
Article
in English
| MEDLINE | ID: mdl-35776908
12.
Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Ann Hematol
; 98(3): 753-762, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30617644
13.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2513-2514, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37154851
14.
Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS.
Am J Hematol
; 93(12): 1524-1531, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30194866
15.
Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
Br J Haematol
; 179(3): 480-487, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28832948
16.
Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Anticancer Drugs
; 27(3): 254-8, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26645891
17.
Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings.
Ann Hematol
; 94(10): 1677-88, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26055139
18.
Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.
Haematologica
; 104(11): e510-e513, 2019 11.
Article
in English
| MEDLINE | ID: mdl-30948486
19.
[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?] / T-Zell-rekrutierende Immuntherapien des B-Zell-Lymphoms bald in allen Therapielinien?
Dtsch Med Wochenschr
; 149(11): 630-637, 2024 May.
Article
in German
| MEDLINE | ID: mdl-38749439
20.
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.
Eur J Cancer
; 204: 114071, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38691878